Described herein is a novel expression system for producing multiple gene products of interest from a single polycistronic construct. In particular, the expression system contains a polycistronic vector capable of expressing functional antibodies in eukaryotic host cells, which vector contains at least the following elements operably linked in the 5' to 3' orientation: a promoter operable in a eukaryotic cell; a DNA sequence encoding at least the variable region of an antibody light chain; an internal ribosome entry site (IRES); and at least one DNA sequence encoding an antibody heavy chain. Also disclosed are mammalian cells containing the polycistronic expression vector, and a method of producing functional antibodies in mammalian cells transfected with the polycistronic expression vector.

Polycistronic expression of antibodies

The present invention encompasses engineered Newcastle Disease Virus (NDV) vaccines or compositions The vaccine or composition may be a recombinant vaccine The invention also encompasses recombinant vectors encoding and expressing avian pathogen antigens, more specifically avian influenza proteins, epitopes or immunogens Such vaccines or compositions can be used to protect animals, in particular avian, against disease

Newcastle disease virus vectored avian vaccines

Turkey herpesvirus (HVT) recombinants or Marek's disease virus (MDV) recombinants contructed by integrating a heterogenous gene, in particular, a heteroantigen gene into the non-essential region of the HVT genome or the MDV genome, thus providing HVT recombinants carrying a foreign gene inserted into the gene region which is the untranslated region of the HVT genome; and vaccines containing these HVT recombinants

Avian infectious herpesvirus recombinants and recombinant vaccines prepared with the use of the same

The present invention encompasses influenza vaccines, in particular canine influenza vaccines. The vaccine may be a recombinant poxvirus vaccine or an inactivated vaccine. The invention also encompasses recombinant poxvirus vectors encoding and expressing influenza antigens, epitopes or immunogens which can be used to protect animals, in particular dogs, against influenza.

Canine influenza vaccines

The present invention relates to recombinant anti-Nipah virus vaccines and the administration of such vaccines to animals, advantageously pigs. Advantageously, the anti- Nipah virus vaccine may comprise a recombinant avipox virus containing a Nipah virus glycoprotein gene. The invention encompasses methods of vaccinating animals, advantageously pigs, by administration of anti-Nipah virus vaccines that may comprise a recombinant avipox virus that may contain a Nipah virus glycoprotein gene.

Nipah virus vaccines

The living recombinant avian vaccine comprises, as a vector, an ILTV virus comprising and expressing at least one heterologous nucleotide sequence, this nucleotide sequence being inserted in the insertion locus defined between the nucleotides 1624 and 3606 at the SEQ ID NO: 5. The vaccine may in particular comprise a sequence coding for an antigen of an avian pathogenic agent selected among the group consisting of the Newcastle disease virus (NDV), the infections bursal virus (IBDV), the Marek disease virus (MDV), the infectious bronchitis virus (IBV), the chicken anaemia virus (CAV), thee chicken pneumovirosis virus, preferably under the control of a strong eukariotic promoter. A multivalent vaccine formula is also disclosed.

Avian recombinant live vaccine using, as vector, the avian infectious laryngotracheitis virus

The living recombinant avian vaccine comprises, as a vector, an ILTV virus comprising and expressing at least one heterologous nucleotide sequence, this nucleotide sequence being inserted in the insertion locus defined between the nucleotides 1624 and 3606 at the SEQ ID NO: 5. The vaccine may in particular comprise a sequence coding for an antigen of an avian pathogenic agent selected among the group consisting of the Newcastle disease virus (NDV), the infections bursal virus (IBDV), the Marek disease virus (MDV), the infectious bronchitis virus (IBV), the chicken anaemia virus (CAV), the chicken pneumovirosis virus, preferably under the control of a strong eukariotic promoter. A multivalent vaccine formula is also disclosed.

Bublot Michel

Papers

Avian recombinant live vaccine using, as vector, the avian infectious laryngotracheitis virus

Living recombinant avian vaccine, using as a vector the infectious avian laryngotracheitis virus